Rabbit monoclonal antibodies are typically derived from hybridomas, which are commonly poorly characterized and can exhibit high batch-to-batch variability. Hybridoma library screening is limited in size (104-105), often missing rare clones that recognize important, less immunodominant epitopes. B-cell cloning methods suffer from similar limitations in library size and can lose additional clones due to poor gene recovery. Additionally, these approaches are ‘one-shot’ strategies—if they fail on the first attempt, it is impossible to return to the same immune source to obtain new clones.Rabbit hybridoma cells are also known to express poorly.
Recently, single B-cell cloning and deep sequencing approaches are used for rabbit monoclonal antibody development. However, even these methods are lacking the selection of antibodies with desired affinity and specificity and they have to be recombinantly made one by one to test their bindings and functions.
In contrast, Abwiz Bio's proprietary recombinant rabbit monoclonal antibody development platform, RabWizTM platform combines the power of the rabbit immune response with the large library sizes (5x109- 2 x 1010) of phage libraries. Our libraries are archived indefinitely as DNA after library construction, allowing for unique selection strategies including epitope masking with dominant (non-functional) clones to obtain rare neutralizing antibodies. Once the candidate clones are selected and converted to IgG, they tend to express very well unlike hybridoma cells.